Atorvastatin as GVHD Prophylaxis for Allogeneic Hematopoietic Cell Transplantation
Information source: Medical College of Wisconsin
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Graft vs Host Disease
Intervention: Atorvastatin calcium (Drug)
Phase: Phase 2
Status: Recruiting
Sponsored by: Mehdi Hamadani Official(s) and/or principal investigator(s): Michael Craig, MD, Principal Investigator, Affiliation: West Virginia University Mehdi Hamadani, MD, Principal Investigator, Affiliation: Medical College of Wisconsin
Summary
Hematopoietic stem cell transplantation is a procedure in which a person receives blood
forming stem cells from a person called a "donor". The stem cells can be obtained from the
hollow part of the hip bone or from blood.
A serious problem with this treatment is Graft Versus Host Disease (GVHD). This happens
when stem cells from the donor attack normal cells of the recipient. Currently, there is no
universal standard of care in the United STates to prevent GVHD.
This study is being done to see if a medicine that is used to lower cholesterol can also
help in reducing GVHD.
Patients will receive atorvastatin daily by mouth starting 14 days before stem cell
transplant. They will continue to take atorvastatin until 180 days after transplant. This
medicine may be stopped earlier if there is a bad side effect or a severe GVHD. Patients
will also receive standard treatment to prevent GVHD. Patients will undergo many tests that
are standard for their treatment at West Virginia University (WVU), including blood tests to
check blood counts, kidney function and HIV status; blood test to check for pregnancy; Multi
Gated Acquisition Scan (MUGA scan)or echocardiogram to test heart function; lung function
testing; and bone marrow aspirate or biopsy. Patients will also have the option to provide
blood samples for optional research related to the study.
Clinical Details
Official title: Phase II Study of Atorvastatin, Micro-dose Methotrexate and Tacrolimus Administered Only to Transplant Recipients for the Prophylaxis of Acute Graft-versus-host Disease Following Allogeneic Hematopoietic Cell Transplantation
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Primary outcome: Determine efficacy of atorvastatin/tacrolimus/methotrexate in preventing GVHDAssess the safety of an atorvastatin/tacrolimus methotrexate regimen in patients undergoing allogeneic HSCT
Secondary outcome: To assess rates of chronic GVHD
Detailed description:
Acute graft-versus-host disease (GVHD) is one of the most frequent complications after
allogeneic hematopoietic stem cell transplantation (HSCT) (1). It develops in 30-75% of
recipients of allogeneic HSCT depending on the degree of histocompatibility between the
donor and the recipient, number of T-cells in the graft, recipient's age and GVHD
prophylactic regimen used (2-4). Novel strategies designed to effectively prevent the
development of this life threatening complication of allogeneic transplantation are urgently
needed.
Eligibility
Minimum age: 18 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Patient Eligibility Criteria:
- Patients with a history of a hematological malignancy or bone marrow failure syndrome
suitable for allogeneic stem cell transplantation in the opinion of treating
transplant physician.
- Patients aged 18-75 years of age are eligible. Patients with age > 18 and ≤ 50 years
will be eligible for myeloablative conditioning (MAC), while patients > 50 years of
age, or those with previous history of autologous transplantation, high hematopoietic
cell transplant comorbidity index (HCT-CI) score (>2), and baseline diagnosis of
hodgkin's lymphoma, chronic lymphocytic leukemia and follicular lymphoma will be
suitable for reduced intensity conditioning (RIC) transplantation (however intensity
of conditioning regimen will remain at the discretion of treating physician).
- All patients must have at least one suitable human leukocyte antigen (HLA)-matched
sibling or unrelated donor according to transplant center's guidelines (for selection
of appropriate sibling donor).
- Patient must provide informed consent.
- Left ventricular ejection fraction ≥ 40%. No uncontrolled arrhythmias or uncontrolled
New York Heart Association class III-IV heart failure.
- Bilirubin ≤ 2 x the upper limit of normal (ULN) and aspartate aminotransferase (AST),
and alanine aminotransferase (ALT) ≤ 3 x ULN; and absence of hepatic cirrhosis. For
patients with Gilbert's syndrome, bilirubin ≤ 3 x ULN is permitted.
- Adequate renal function as defined by a serum creatinine clearance of ≥ 40% of normal
calculated by Cockcroft-Gault equation.
- DLCOcor (carbon monoxide diffusing capacity; corrected for hemoglobin) or forced
expiratory volume at one second (FEV1) or DL/VA ≥ 40% of predicted (a pulmonary
function test).
- Karnofsky performance status > 70.
- A negative pregnancy test will be required for all women of child bearing potential.
Breast feeding is not permitted.
- Patients with positive HIV serology are eligible.
- No evidence of active bacterial, viral or fungal infection at the time of transplant
conditioning.
- Patients with history of intolerance or allergic reactions with atorvastatin will not
be eligible.
- Patients who have previously been taking atorvastatin or any other statin drug will
be eligible as long as there is no contraindication to switch to atorvastatin
(40mg/day) in the opinion of the treating physician.
- Patients undergoing a T-cell depleted allogeneic transplantation will not be
eligible.
- Patients receiving conditioning regimens containing antithymocyte globulin, and/or
campath will not be eligible.
- Method of stem-cell collection from the sibling donor will be at the discretion of
the treating physician. Although it is anticipated that majority of sibling donors
will undergo Granulocyte colony-stimulating factor(G-CSF) induced stem cell
mobilization; however donors undergoing bone marrow harvest or stem cell mobilization
with experimental agents (e. g. plerixafor) will remain eligible for the study.
Locations and Contacts
West Virginia University Hospitals Mary Babb Randolph Cancer Center, Morgantown, West Virginia 26506, United States; Recruiting Pam Bunner, MT, Phone: 304-598-4511, Email: bunnerp@wvuhealthcare.com Crystal Street, MT, Phone: 304-598-4512, Email: streetc@wvuhealthcare.com Michael Craig, MD, Principal Investigator William Tse, MD, Sub-Investigator Soumit Basu, MD, PhD, Sub-Investigator Laura Gibson, PhD, Sub-Investigator Jame Abraham, MD, Sub-Investigator William Petros, PharmD, Sub-Investigator Aaron Cumpston, PharmD, Sub-Investigator Scot C Remick, MD, Sub-Investigator Jeffrey Vos, MD, Sub-Investigator Abraham Kanate, MD, Sub-Investigator
Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin 53226, United States; Recruiting Cancer Center Clinical Trials Office, Phone: 866-680-0505, Ext: 8900, Email: cccto@mcw.edu Cancer Center Clinical Trials Office, Phone: 414-805-8900, Email: cccto@mcw.edu Mehdi Hamadani, MD, Principal Investigator
Additional Information
Related publications: Deeg HJ. How I treat refractory acute GVHD. Blood. 2007 May 15;109(10):4119-26. Epub 2007 Jan 18. Review. Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, Fay JW, Nademanee A, Antin JH, Christiansen NP, van der Jagt R, Herzig RH, Litzow MR, Wolff SN, Longo WL, Petersen FB, Karanes C, Avalos B, Storb R, Buell DN, Maher RM, Fitzsimmons WE, Wingard JR. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood. 1998 Oct 1;92(7):2303-14. Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM, Przepiorka D, Davies S, Petersen FB, Bartels P, Buell D, Fitzsimmons W, Anasetti C, Storb R, Ratanatharathorn V. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood. 2000 Sep 15;96(6):2062-8. Antin JH, Kim HT, Cutler C, Ho VT, Lee SJ, Miklos DB, Hochberg EP, Wu CJ, Alyea EP, Soiffer RJ. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood. 2003 Sep 1;102(5):1601-5. Epub 2003 May 1. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89-118. Review.
Starting date: September 2012
Last updated: June 18, 2015
|